IDEAS home Printed from https://ideas.repec.org/a/gam/jijerp/v19y2022i21p14549-d964525.html
   My bibliography  Save this article

The Quality of Life and Medication Adherence in Patients with Multiple Sclerosis—Cross-Sectional Study

Author

Listed:
  • Aleksandra Kołtuniuk

    (Department of Nursing and Obstetrics, Faculty of Health Science, Wroclaw Medical University, 51-618 Wroclaw, Poland)

  • Aleksandra Pytel

    (Department of Nursing and Obstetrics, Faculty of Health Science, Wroclaw Medical University, 51-618 Wroclaw, Poland)

  • Dorota Krówczyńska

    (Cardinal Stefan Wyszynski Institute of Cardiology, 04-628 Warsaw, Poland
    Department of Nursing and Obstetrics, Collegium Mazovia, 08-110 Siedlce, Poland)

  • Justyna Chojdak-Łukasiewicz

    (Department of Neurology, Wroclaw Medical University, 50-529 Wroclaw, Poland)

Abstract

Multiple sclerosis (MS) is a chronic, degenerative autoimmune inflammatory disease of the central nervous system. MS is characterized by a wide range of symptoms and unpredictable prognosis, which can severely affect patient quality of life (QOL). The treatment strategy includes acute relapse treatment, disease-modifying treatment (DMT), and symptomatic therapy. Adherence to long-term DMTs is essential in order to maximize the therapeutic effects for MS and is crucial to health-related quality of life (HRQOL). This study aimed to evaluate the relationship between QOL and adherence to DMTs in MS patients. A group of 344 patients (73% females) aged 39.1 years with relapsing-reemitting MS were included. The Multiple Sclerosis International Quality of Life (MusiQOL) and the Multiple Sclerosis Treatment Adherence Questionnaire (MS-TAQ) were used. An injection of interferon (IFN)-β1b was used in 107 patients, IFN-β1a in 94 patients, and glatiramer acetate in 34 patients. The oral treatment includes teriflunomide in 14 patients, dimethyl fumarate in 86 patients, and fingolimod in nine patients. No statistically significant differences ( p > 0.05) were observed in adherent (ADH) vs. non-adherent patients (non-ADH) in MusiQOL. The total adherence rate was 72% (MS-TAQ). An analysis of the univariate logistic regression model showed an effect of only the activities of daily living (ADL) and relationship with the healthcare system (RHCS) domains on the level of adherence to treatment recommendations. The other variables studied do not affect the level of adherence. Higher QOL levels in the ADL and RHCS domains affect medication adherence in MS patients. Our findings could help manage MS patients, promoting interventions on ADLs and good relationships with healthcare providers to improve their adherence to therapy and result in better QOL.

Suggested Citation

  • Aleksandra Kołtuniuk & Aleksandra Pytel & Dorota Krówczyńska & Justyna Chojdak-Łukasiewicz, 2022. "The Quality of Life and Medication Adherence in Patients with Multiple Sclerosis—Cross-Sectional Study," IJERPH, MDPI, vol. 19(21), pages 1-15, November.
    • Handle: RePEc:gam:jijerp:v:19:y:2022:i:21:p:14549-:d:964525
    as

    Download full text from publisher

    File URL: https://www.mdpi.com/1660-4601/19/21/14549/pdf
    Download Restriction: no
    File URL: https://www.mdpi.com/1660-4601/19/21/14549/
    Download Restriction: no
    ---><---

    References listed on IDEAS

    as
    1. Kerstin Hansen & Katrin Schüssel & Marita Kieble & Johanna Werning & Martin Schulz & Robert Friis & Dieter Pöhlau & Norbert Schmitz & Joachim Kugler, 2015. "Adherence to Disease Modifying Drugs among Patients with Multiple Sclerosis in Germany: A Retrospective Cohort Study," PLOS ONE, Public Library of Science, vol. 10(7), pages 1-12, July.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.

      Corrections

      All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:gam:jijerp:v:19:y:2022:i:21:p:14549-:d:964525. See general information about how to correct material in RePEc.

      If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

      If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

      If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

      For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: MDPI Indexing Manager (email available below). General contact details of provider: https://www.mdpi.com .

      Please note that corrections may take a couple of weeks to filter through the various RePEc services.

      IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.